The global nucleic acid labeling market is projected to exhibit considerable CAGR during the forecast period. The growing demand for personalized medicines for the treatment of several diseases is promoting the growth of the market. This is due to the fact that several genetic tests need to be taken into account for the preparation of personalized medicine as these tests will eventually reveal the various conditions of the patients. Further, the personalized medicines have the potential to modify therapy with the best response and highest safety margin to ensure better patient care. By the use of personalized medicines, each patient can receive earlier diagnoses, risk assessments, and optimal treatments.
Browse the full report description of "Global Nucleic Acid Labeling Market Size, Share & Trends Analysis Report by Labeling Type (Biotin Based, Fluorescent, Radioactive Phosphates, Others), by Application (Polymerase Chain Reaction (PCR), Microarray, In-Situ Hybridization, DNA Sequencing, and Others), by End-user (Hospitals, Diagnostic Centres, Others), Forecast 2019-2025" at https://www.omrglobal.com/industry-reports/nucleic-acid-labeling-market
The personalized medicine holds promise for improving healthcare while lowering costs which is expected to be a positive indicator for the growth of the global nucleic acid labeling market.The biopharmaceutical companies closely doubled their R&D investment in personalized medicine over the past five years and suppose to increase their investment in the near future. The US FDA has received a significant number of personalized medicines for its approval in the past years. A significant rise in the US FDA approvals for personalized medicines is supporting the growth in genomics researches which in turn is anticipated to create the demand for nucleic acid labeling. For instance, as per the Personalized Medicine Coalition, in 2018, 25 of the 59 new molecular entities (NMEs) that are approved by the US FDA are personalized medicines, which comprises 42% of all new drug approvals.
The Coalition classified 34% of NMEs as personalized medicines in 2017, 28% in 2015; 27% in 2016. The US FDA is making efforts to facilitate access to genomic testing and integrating real-world evidence into its regulatory framework. As a result, genetic tests related to the treatment of several diseases to drive the demand for the nucleic acid labeling market. The rising prevalence of chronic diseases such as heart diseases, cancer, and diabetes across the globe is further creating the demand for personalized medicines for their treatment which in turn is anticipated to drive the growth of the global market. New England Biolabs, Inc., GE Healthcare, Merck KgaA, Thermo Fisher Scientific Corp., General Electric Co., and Promega Corp. among others are the key players providing nucleic acid labeling for personalized medicine.
Global Nucleic Acid Labeling Market-Segmentation
By Labeling Type
By Application
By End-User
Global Nucleic Acid Labeling Market– Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/nucleic-acid-labeling-market